ORCID Profile
0000-0001-7211-1891
Current Organisations
University of Melbourne
,
Murdoch Children's Research Institute
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 10-1989
DOI: 10.1111/J.1445-5994.1989.TB00305.X
Abstract: Balloon aortic valvuloplasty has been used as treatment for selected patients with severe aortic stenosis. We report our experience of 11 procedures, performed on ten patients between October 1987 and June 1988. The peak aortic systolic gradient was reduced by 53% from 77 +/- 22 to 37 +/- 14 mmHg (p less than 0.0001) whilst cardiac output did not change significantly (4.1 +/- 1.7 to 3.8 +/- 1.6 (p less than 0.0001) whilst cardiac output did not change significantly (4.1 +/- 1.7 to 3.8 +/- 1.6 L/min). Aortic valve area was increased by 50%, from 0.4 +/- 0.2 to 0.6 +/- 0.2 cm2 (p less than 0.0001). Initial symptomatic improvement was achieved in eight patients. Echocardiographically demonstrated aortic regurgitation did not increase after valvuloplasty. There were no deaths during the procedure, no embolic events and no femoral artery complications. The mean follow-up for survivors was 9 +/- 3 months. Five patients died and three had symptom recurrence at an average of 13 weeks (six-24 weeks). Only two patients reported a continued improvement in symptoms. Balloon aortic valvuloplasty produced a small increase in aortic valve area and a satisfactory initial clinical response, but there was a high incidence of symptom recurrence. The procedure may have a role in the short-term palliation of severely symptomatic patients who are unable to have aortic valve replacement.
Publisher: Wiley
Date: 26-02-2020
Publisher: Wiley
Date: 06-09-2022
DOI: 10.1111/TRF.17084
Abstract: Transfusion Requirements in Cardiac Surgery III (TRICS III), a multi‐center randomized controlled trial, demonstrated clinical non‐inferiority for restrictive versus liberal RBC transfusion for patients undergoing cardiac surgery. However, it is uncertain if transfusion strategy affects long‐term health‐related quality of life (HRQOL). In this planned sub‐study of Australian patients in TRICS III, we sought to determine the non‐inferiority of restrictive versus liberal transfusion strategy on long‐term HRQOL and to describe clinical outcomes 24 months postoperatively. The restrictive strategy involved transfusing RBCs when hemoglobin was .5 g/dl the transfusion triggers in the liberal group were: .5 g/L intraoperatively, .5 g/L in intensive care, or .5 g/dl on the ward. HRQOL assessments were performed using the 36‐item short form survey version 2 (SF‐36v2). Primary outcome was non‐inferiority of summary measures of SF‐36v2 at 12 months, (non‐inferiority margin: −0.25 effect size restrictive minus liberal scores). Secondary outcomes included non‐inferiority of HRQOL at 18 and 24 months. Six hundred seventeen Australian patients received allocated randomization HRQOL data were available for 208/311 in restrictive and 217/306 in liberal group. After multiple imputation, non‐inferiority of restrictive transfusion at 12 months was not demonstrated for HRQOL, and the estimates were directionally in favor of liberal transfusion. Non‐inferiority also could not be concluded at 18 and 24 months. Sensitivity analyses supported these results. There were no differences in quality‐adjusted life years or composite clinical outcomes up to 24 months after surgery. The non‐inferiority of a restrictive compared to a liberal transfusion strategy was not established for long‐term HRQOL in this dataset.
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Peter Summers.